Insider Selling: Cerus (NASDAQ:CERS) Insider Sells $89,400.00 in Stock

Cerus Corporation (NASDAQ:CERS) insider Chrystal Jensen sold 30,000 shares of Cerus stock in a transaction on Monday, August 17th. The shares were sold at an average price of $2.98, for a total value of $89,400.00. Following the completion of the sale, the insider directly owned 936,657 shares of the company’s stock, valued at $2,791,237.86. This trade represents a 3.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Chrystal Jensen also recently made the following trade(s):

• On Tuesday, June 30th, Chrystal Jensen sold 24,329 shares of Cerus stock. The shares were sold at an average price of $2.94, for a total value of $71,527.26.

Cerus Stock Up 3.3%

Shares of NASDAQ CERS opened at $2.85 on Thursday. Cerus Corporation has a 1 year low of $1.15 and a 1 year high of $3.47. The firm has a market capitalization of $574.33 million, a PE ratio of -95.00 and a beta of 1.81. The company has a current ratio of 1.83, a quick ratio of 1.07 and a debt-to-equity ratio of 0.49. The firm’s 50-day moving average is $2.82 and its 200-day moving average is $2.44.

Cerus (NASDAQ:CERS) last released its earnings results on Thursday, July 30th. The biotechnology company reported ($0.01) EPS for the quarter, hitting analysts’ consensus estimates of ($0.01). Cerus had a negative net margin of 3.06% and a negative return on equity of 10.19%. The firm had revenue of $63.30 million during the quarter, compared to analyst estimates of $62.90 million. Equities analysts expect that Cerus Corporation will post -0.04 EPS for the current year.

Analyst Ratings Changes

CERS has been the topic of a number of analyst reports. Wall Street Zen downgraded shares of Cerus from a “buy” rating to a “hold” rating in a research report on Saturday, August 15th. BTIG Research upgraded shares of Cerus from a “neutral” rating to a “buy” rating and set a $4.00 price objective for the company in a report on Friday, May 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cerus in a research note on Thursday, June 18th. Finally, Zacks Research upgraded shares of Cerus from a “strong sell” rating to a “hold” rating in a report on Thursday, April 30th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $4.00.

Institutional Investors Weigh In On Cerus

Large investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC raised its position in shares of Cerus by 152.4% during the first quarter. Cubist Systematic Strategies LLC now owns 104,101 shares of the biotechnology company’s stock worth $145,000 after purchasing an additional 62,854 shares during the period. AQR Capital Management LLC grew its position in shares of Cerus by 291.6% in the 1st quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company’s stock valued at $1,986,000 after purchasing an additional 1,064,133 shares during the period. Millennium Management LLC increased its stake in Cerus by 12.0% during the 1st quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company’s stock worth $4,479,000 after purchasing an additional 344,395 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Cerus during the 1st quarter worth approximately $32,000. Finally, Rhumbline Advisers raised its holdings in Cerus by 6.8% during the 2nd quarter. Rhumbline Advisers now owns 268,946 shares of the biotechnology company’s stock worth $379,000 after buying an additional 17,039 shares during the period. 78.37% of the stock is currently owned by institutional investors.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.